美通社

2024-07-09 20:00

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure, has recently announced its partnership with the Pulmonary Hypertension Association (PHA). This partnership not only underscores Pulnovo Medical's growing global influence but also empowers PHA's mission to extend and improve the lives of those affected by pulmonary hypertension (PH) worldwide.

Pulnovo Medical and the PHA are united by a collective vision to a future where pulmonary hypertension is better understood and more efficiently treated. Pulnovo Medical's PADN technology, an innovative interventional therapy in the field of pulmonary hypertension, provides a new and beneficial solution for patients troubled by traditional drug treatments. Currently Pulnovo Medical is conducting global trials in US and Europe. This strategic partnership aims to combine Pulnovo Medical's cutting-edge PADN therapies for Pulmonary Hypertension with PHA's extensive network to enhance public awareness and improve the care of PH patients globally. As a member of PHA, Pulnovo Medical will actively participate in PHA's educational programs, research projects and advocacy campaigns. Our collaboration will harness the urgency of our shared mission to make a lasting impact on pulmonary hypertension patients worldwide.

About PHA

The PHA was founded in 1991 in Florida and evolved into an international community of more than 16,000 people with PH, caregivers, family members and health care professionals. As one of the largest and oldest pulmonary hypertension association in the world, the PHA acts as a trusted liaison between the pulmonary hypertension community and industry and academic partners.

About PADN

Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure, inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.

About Pulnovo Medical

Pulnovo Medical Limited, is a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure, is committed to leveraging our deep expertise in the science of breakthrough technologies with the goal to market our innovative therapeutic solutions and benefit patients around the world.

For more information, please visit: www.pulnovomed.us

source: Pulnovo Medical

【你點睇】美國總統拜登卸任前宣布特赦兒子亨特拜登,你認為美國民主及法治制度是否已經受損?► 立即投票

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞睇住賞Maxcare美天膝健寶(價值HK$2,699)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

傾力救市

說說心理話

Watche Trends 2024

北上食買玩

Art Month 2024

理財秘笈

秋天養生食療

消委會報告

山今養生智慧

輕鬆護老